“
TL;DR
This narrative review synthesizes preclinical research showing that the gluconeogenic enzyme PCK1 is expressed in various cancers and has both metabolic and non-metabolic roles in tumor progression.
Biochemistry and Biophysics Reports · 6 authors, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review synthesizes preclinical research showing that the gluconeogenic enzyme PCK1 is expressed in various cancers and has both metabolic and non-metabolic roles in tumor progression.
It synthesizes existing literature to highlight that despite PCK1 being a rate-limiting enzyme in gluconeogenesis, it is functionally expressed in tumors from both gluconeogenic and non-gluconeogenic organs. The review describes PCK1's paradoxical role in cancer metabolism and progression, indicating it has metabolic functions as well as non-metabolic roles in tumor development. The authors note that while some mechanisms have been proposed, a clear explanation for its paradoxical effect remains unknown. The conclusion emphasizes the need for further cancer-specific research on PCK1's genomic sequencing, structure, expression, and biochemical mechanisms to understand its precise action and potential as a therapeutic target. The review does not report original experimental data but consolidates findings from numerous cited studies.